Health care professionals’ attitudes toward cancer gene panel testing

Klugman, Susan; Schnabel, Freya; Alim, Ishraq; Loke, Johnny; Arun, Banu K.; Kim, Jennifer Chun; Ostrer, Harry

doi:10.1111/tbj.14210

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Should the reported high sensitivity of CR-B be conserved over larger studies, it would meet the criteria favored by recent survey respondents to a new germline cancer risk assessment test: high sensitivity and specificity, rapid turnaround time, and low cost. 17 …”

Section: Discussionmentioning

confidence: 99%

Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells

Loke

Alim

Yam³

et al. 2022

Human Genetics and Genomics Advances

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells

Loke

Alim

Yam³

et al. 2022

Human Genetics and Genomics Advances

Self Cite

View full text Add to dashboard Cite

Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia

Kwong,

Tan,

Ryu

2024

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

AimThis study assesses current practices and challenges in genetic testing and counseling (GT and C) for breast cancer gene (BRCA)1/2 mutations in Asia, considering the increased risk of ovarian cancer (OC) and breast cancer (BC) in women carrying these mutations.MethodsInsights were gathered through a questionnaire from breast surgeons, gynecologists, oncologists, and genetic clinicians in 10 Asian countries: Thailand, Hong Kong, South Korea, India, Vietnam, Malaysia, the Philippines, Taiwan, Singapore, and Indonesia. The questionnaire covered their knowledge, attitudes, and practices in GT and C for BRCA1/2 mutations, along with information on perceived gaps and unmet needs in the region.ResultsA total of 61 specialists participated in the survey. GT and C for BRCA1/2 mutations were less frequently offered in Asia compared to Western countries. Among the guidelines used, the National Comprehensive Cancer Network (NCCN) guidelines alone or in combination with other guidelines (American Society of Clinical Oncology [ASCO], National Institute for Health and Clinical Excellence [NICE], and European Society for Medical Oncology [ESMO]) were preferred for both BC and OC. Limited access to genetic counselors posed a significant challenge, resulting in delayed or no GT. Pretest genetic counseling was provided by the respondents themselves. Germline testing was preferred for BC, whereas both germline and somatic testing were preferred for OC, with the most preferred option being a multipanel germline test.ConclusionDisparities exist in GT and C practices between Asian and Western countries. To address this, steps, such as patient and doctor education, increased accessibility and affordability of GT and C services, and improved infrastructure for identifying gene mutations, should be taken.

show abstract

Health care professionals’ attitudes toward cancer gene panel testing

Cited by 2 publications

References 9 publications

Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells

Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells

Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia

Contact Info

Product

Resources

About